

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
**Army156A**

In Re Application Of: **Eckels et al.**

Serial No.  
**not known**

Filing Date  
**July 24, 2003**

Examiner  
**not known**

Group Art Unit  
**not known**

Title: **Live-Attenuated Multivalent Dengue Vaccine**

**(DIVISIONAL APPLICATION OF SERIAL NO. 09/535,117)**

Address to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
Army156A

In Re Application: Eckels et al.

Serial No.  
not known

Filing Date  
July 24, 2003

Examiner  
not known

Group Art Unit  
not known

Live-Attenuated Multivalent Dengue Vaccine

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on \_\_\_\_\_ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\_\_\_\_\_  
Signature of Person Mailing Correspondence

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.



\_\_\_\_\_  
Signature

Dated: July 24, 2003

Marlana Titus, Reg. No. 35,843  
for Elizabeth Arwine, Reg. No. 45,867  
Attorney for applicant  
U.S. Army Medical Research and Materiel Command  
504 Scott Street  
Ft. Detrick, MD 21702-5012  
(301) 762-8214

cc:

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re PATENT APPLICATION of  
Eckels et al.

Group Art Unit: not known

Serial No: not known  
Divisional app. of Serial No.: 09/535,117

Examiner: not known

Filed: July 24, 2003

FOR: Live-Attenuated Multivalent Dengue Vaccine

\* \* \* \* \*

July 24, 2003


**STATEMENT PURSUANT TO 37 CFR 1.198(d)**

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

Sir:

In connection with the above-identified divisional application, Applicants have filed concurrently herewith an Information Disclosure Statement and corresponding PTO-1449 form citing a number of references. Copies of all the references cited on the PTO-1449 form were submitted and considered in parent application Serial No. 09/535,117 (filed 3-24-00). Pursuant to 37 CFR 1.198(d), copies of these references are not required to be supplied in this divisional application.

By: \_\_\_\_\_

  
Marlana K. Titus, Reg. No. 35,843  
for: Elizabeth Arwine, Reg. No. 45,867  
Attorney for Applicants  
U.S. Army Medical Research  
and Materiel Command  
504 Scott St., ATTN: MCMR-JA  
Fort Detrick, MD 21702-5012  
(301)762-8214

(Use several sheets if necessary)

**Army 156A**

Div. app. of 09/535,117

Eckels et al.

**July 24, 2003**

not known

[illegible][illegible]

	A	Botstein and Shortle, 1985, "Strategies and applications of in vitro mutagenesis", Science, Vol. 229, No. 4719, pp. 1193-1201.
	B	Clarke and Casals, 1958, "Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses", Am. J. Trop. Med. Hyg., 7, 561-573.

DATE CONSIDERED

PAGE 1 OF 10

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		Docket Number (Optional)	Application Number	
		Army156A		Div. app. of 09/535,117
		Applicant(s)		Group Art Unit
		Eckels et al.		
		Filing Date	not known	
		July 24, 2003		

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
C	Halstead et al., 1984, "Selection of attenuated Dengue 4 viruses by serial passage in primary kidney cells," Am J. Trop. Med. Hyg. 33(4), pp. 654-665.
D	Halstead et al., 1984, "Selection of attenuated Dengue 4 viruses by serial passage in primary kidney cells," Am J. Trop. Med. Hyg. 33(4), pp. 666-671.
E	Halstead et al., 1984, "Selection of attenuated Dengue 4 viruses by serial passage in primary kidney cells," Am J. Trop. Med. Hyg. 33(4), pp. 672-678.
F	Halstead et al., 1984, "Selection of attenuated Dengue 4 viruses by serial passage in primary kidney cells," Am J. Trop. Med. Hyg. 33(4), pp. 679-683.
G	Hayflick, 1988, "History of cell substrates used for human biologicals", Symposium on Continuous Cell Lines as Substrates for Biologicals, Arlington, Virginia, USA, pp. 11-26.
H	Hoke et al., 1990, "Preparation of an attenuated Dengue 4 virus vaccine", Am J. Top. Med. Hyg., 43(2), pp. 219-226.
I	Marchette, 1990, "Preparation of an attenuated Dengue 4 virus vaccine", Am J. Top. Med. Hyg., 43(2), pp. 212-218.
K	Mizrahi, ed., Viral Vaccines, "WHO Attitude to Viral Vaccines", Wiley-Liss, New York (1990), pp. 39-60.
L	Putnak et al, 1996, "Development of a purified, inactivated, Dengue-2 virus vaccine prototype in vero cells: immunogenicity and protection in mice nad Rhesus monkeys," J. Infectious Dis., 174, pp.1176-84.
M	Russell, et al., "A plaque reduction test for dengue virus neutralizing antibodies", J. Immunology, Vol. 99, No. 2, 1967, pp.285-290.
N	Scott, 1983, "Dengue 2 vaccine: Dose response in volunteers in relation to yellow fever immune status," J. Infectious Diseases, Vol., 148, No. 6, pp.1055-1060.
O	Sukhavachana et al, 1966, "Tissue culture techniques for the study of dengue viruses", Abreges des Communications, Bull. WHO 35, pp. 65-66.
<div style="display: flex; justify-content: space-between;"> <span>MINER</span> <span>DATE CONSIDERED</span> </div>	

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

Army156A

Application Number

Div. app. of 09/535,117

Applicant(s)

Eckels et al.

Filing Date

July 24, 2003

Group Art Unit

not known

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

P

Zoller and Smith, 1984, Laboratory Methods, "Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template", DNA, Vol. 3, No. 6, pp.479-488.

Q

Bhamarapravati, 1987, "Immunization with a live attenuated dengue-2-virus candidate vaccine: clinical, immunological and biological responses in adult volunteers", Bull. WHO, 65(2), pp.189-195.

R

Conrad et al., "Infection with Nippostrongylus Brasiliensis or injection of anti-IgD antibodies markedly enhances Fc-receptor-mediated interleukin 4 production by non-B, non-T cells", J. Exp. Med., Vol. 171, pp.1497-1508.

S

Dharakul, et al., "Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus Type 2 candidate vaccine", J. Infect. Dis., Vol. 170, pp. 27-33.

T

Edelman et al., "A live attenuated Dengue-1 vaccine candidate passaged in primary dog kidney cell culture is attenuated and immunogenic for humans", 1994, Am. J. Trop. Med. Hyg., 170, pp. 1448-1455.

U

Halstead, 1978, "Studies on the attenuation of Dengue 4", Asian J. Infectious Dis., Vol. 2, pp. 112-117.

V

Halstead, 1970, "Long 'cure' improves results of pig heterograft heart valves," JAMA, Vol. 211, No. 6, pp. 911-916.

W

Johnson and Roehrig, "New mouse model for Dengue virus vaccien testing", J. Virology, Jan. 1999, Vol. 73, No. 1, pp. 783-786.

X

Kontny et al., "Gamma interferon augments Fcy receptor-mediated Dengue virus infection of human monocytic cells", J. Virology, Nov. 1988, Vol. 62, No. 11, pp. 3928-3933.

Y

Kurane et al., "Dengue virus-specific human T cell clones", J. Exp. Med., Vol. 170, 1989, pp. 763-775.

Z

Kurane et al., "Activation of T lymphocytes in dengue virus infections", J. Clin. Invest., Vol. 88, 1991, pp. 1473-1480.

AA

Kurane et al., "T cell activation in vivo by Dengue virus infection", J. Clin. Lab. Immunol., 1995, vol. 46, pp.35-40.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Docket Number (Optional)

Army156A

Application Number

Div. app. of 09/535,117

Applicant(s)

Eckels et al.

Filing Date

July 24, 2003

Group Art Unit

not known

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BB

Peters, "Actions of cytokines on the immune response and viral interactions: an overview", Hepatology, Vol. 23, 1996, pp. 909-916.

CC

Sittisombut et al., "Lack of augmenting effect of interferon- $\gamma$  on Dengue virus multiplication in human peripheral blood monocytes", J. Medical Virology 45:43-49, 1995.

DD

Sabin, 1959, "Dengue", Viral and Rickettsial Infections of Man, Philadelphia: JB Lippincott Company, pp. 361-373.

EE

Simmons et al., "Experimental Studies of Dengue", 1931, Manila BUreau of Printing, pp. 1-489.

FF

Wisseman and Sweet, "Immunological studies with Group B arthropod-borne viruses", Am J. Trop. Med. Hyg., Vol. 11, pp. 570-575 (1962).

GG

Yuill et al., "Dengue-virus recovery by direct and delayed plaques in LLC-MK2 cells", Am. J. Trop. Med. Hyg., Vol 17, 1968, pp. 441-448.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>	Docket Number (Optional) <b>Army156A</b>	Application Number <b>Div. app. of 09/535,117</b>
	Applicant(s) <b>Eckels et al.</b>	
	Filing Date <b>July 24, 2003</b>	Group Art Unit <b>not known</b>

[illegible][illegible]

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
A	Edelman, et al., "A Live Attenuated Dengue-1 Vaccine Candidate (45A25) Passaged in Primary Dog Kidney Cell Culture Slts Attenuated and Immunogenic for Humans", J. Infectious Diseases, 1994:170:1448-1455 (December).	
B	Angsubharkorn et al., "Dengue-3 (16562) PGMK 33 Vaccine: Neurovirulence, Viremia and Immune Responses in Macaca Fascicularis", Southeast Asian J. Trop. Med. Public Health, Vol. 25, No. 3, September 1994.	
		DATE CONSIDERED

EXNER

Form PTO-A820  
(also form PTO-1449)

Patent and Trademark Office • U.S. DEPARTMENT OF COMMERCE

SHEET 8 OF 10



**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Docket Number (Optional)

Army156A

Application Number

Div. app. of 09/535,117

Applicant(s)

Eckels et al.

Filing Date

July 24, 2003

Group Art Unit

not known

\*EXAMINER  
INITIAL

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

C

(XP-002150293) Sun et al., Program Abstracts from the First Annual Conference on Vaccine Research, May 30-June 1, 1998, "Phase I Study of Two Doses of Monovalent Live-Attenuated Dengue Virus Vaccines" (2 pages).

D

Vaughn, et al., "Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers", Vaccine, Vol. 14, No. 4, pp. 329-336, 1996.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

P09B/REV04

SHEET 6 OF 10

not known

SHEET 7 OF 10



(Use several sheets if necessary)

**Army156A**

Div. app. of 09/535,117

Eckels et al.

**July 24, 2003**

not known

[illegible]

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
A	WO 96/40933	12/19/96	International application				

B	PCT International Search Report from international application PCT/US00/08199 (corresponding to 09/535,117), dated October 23, 2000 (9 pages).
C	Jirakanjanakit et al., "The use of <i>Toxorhynchites splendens</i> for identification and quantitation of serotypes contained in the tetravalent live attenuated dengue vaccine", Vaccine, GB Butterworth Scientific. Guildford, Vol. 17, no. 6, Feb. 1999, pages 597-601.

DATE CONSIDERED

**Form PTO-A820**  
**(also form PTO-1449)**

PO9A/REV04

Patent and Trademark Office \* U.S. DEPARTMENT OF COMMERCE

SHEET 9 OF 10

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

Army156A

Application Number

Div. app. of 09/535,117

Applicant(s)

Eckels et al.

Filing Date

July 24, 2003

Group Art Unit

not known

EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

D

Hoke et al., "Preparation of an attenuated Dengue 4 virus vaccine II safety and immuogenicity in humans", American J. of Tropical Medicine & Hygiene, Lawrence, KS, US, Vol. 43, No. 2, August 1990, pages 219-226.

E

D. J. Gubler, "The global pandemic of dengue/dengue haemorrhagic fever: Current status and prospects for the future", Annals Academy of Medicine Singapore, vol. 27, no. 2, March 1998, pages 227-234.

F

Putnak et al., "Development of a purified, inactivated, dengue-2 virus vaccine prototype in vero cells: immunogenicity and protection in mice and rhesus monkeys", J. of Infectious Diseases, vol. 174, no. 6, 1996, pages 1176-1184.

G

Puri Beena et al., "Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells", J. of General Virology, vol. 78, no. 9, 1997, pages 2287-2291.

H

Marchette et al., "Preparation of an attenuated dengue 4 virus vaccine I pre-clinical studies", American J. of Tropical medicine & Hygiene, Lawrence, KS, US, vol. 43, no. 2, August 1990, pages 212-218.

I

Bhamarapravati et al., "Live attenuated tetravalent dengue vaccine", Vaccine, GB Butterworth Scientific Guildford, vol. 18, March 2000, pages 44-47.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.